- B.S. in pharmacy, Fudan University, China
- Ph.D. in pharmaceutical sciences, University of Georgia, Athens, GA
- Postdoctoral Fellow in cancer biology & immunotherapy, National Cancer Institute (NCI/NIH), Bethesda, MD
- Associate Professor of Pharmaceutics and Drug Delivery
- Research Associate Professor in the Research Institute of Pharmaceutical Sciences
- Controlled-release and tissue-specific delivery of small-molecule drugs and biologics, including RNAi, cytokines and antibodies
- Mechanism-driven chemotherapy/immunotherapy combinations for the treatment of solid tumors and infectious diseases
Tan C, Waldmann TA. Proteasome inhibitor PS-341, a potential therapeutic agent for adult T-cell leukemia (ATL). Cancer Res 62, 1083−6 (2002).
Tan C, de Noronha RG, Roecker AJ, Pyrzynska B, Khwaja F, Zhang Z, Zhang H, Teng Q, Nicholson AC, Giannakakou P, Zhou W, Olson JJ, Pereira MM, Nicolaou KC, Van Meir EG. Identification of a novel small-molecule inhibitor of the hypoxia-inducible factor 1 pathway. Cancer Res 65, 605−12 (2005).
Katragadda U, Fan W, Wang Y, Teng Q, Tan C. Combined delivery of paclitaxel and tanespimycin via micellar nanocarriers: pharmacokinetics, efficacy and metabolomic analysis. PLoS One 8, e58619 (2013).
Wang Y, Fan W, Dai X, Katragadda U, Mckinley D, Teng Q, Tan C. Enhanced tumor delivery of gemcitabine via PEG-DSPE/TPGS mixed micelles. Mol Pharmaceutics 11, 1140−50 (2014).
Fan W, Wang Y, Dai X, Shi L, Mckinley D, Tan C. Reduction-responsive crosslinked micellar nanoassemblies for tumor-targeted drug delivery. Pharm Res 32, 1325−40 (2015).
Dai X, Jiang Y, Tan C. Let-7 sensitizes KRAS mutant tumor cells to chemotherapy. PLoS One 10, e0126653 (2015).
Dai X, Tan C. Combination of microRNA therapeutics with small-molecule anticancer drugs: mechanism of action and co-delivery nanocarriers. Adv Drug Del Rev 81, 184−97 (2015).
Dai X, Fan W, Wang Y, Huang L, Jiang Y, Shi L, Mckinley D, Tan W, Tan C. Combined delivery of let-7b microRNA and paclitaxel via biodegradable nanoassemblies for the treatment of KRAS mutant cancer. Mol Pharmaceutics 13, 520−33 (2016).
Dai X, Kaluz S, Jiang Y, Shi L, Mckinley D, Wang Y, Wang B, Van Meir EG, Tan C. A novel small-molecule arylsulfonamide causes energetic stress and suppresses breast and lung tumor growth and metastasis. Oncotarget 8, 99245−60 (2017).
Zhu D, Osuka S, Zhang Z, Reichert ZE, Yang L, Kanemura Y, You S, Devi NS, Bhattacharya D, Takano S, Gillespie GY, Macdonald T, Tan C, Nishikawa R, Nelson WG, Olson JJ, Van Meir EG. BAI1 suppresses medulloblastoma formation by protecting p53 from Mdm2-mediated degradation. Cancer Cell 33, 1−33 (2018).
Kumar V, Mundra V, Peng Y, Wang Y, Tan C*, Mahato RI* (co-corresponding authors). Pharmacokinetics and biodistribution of polymeric micelles containing miRNA and small-molecule drug in orthotopic pancreatic tumor-bearing mice. Theranostics 8, 4033-49 (2018).
Fitts CA, Ji N, Li Y, Tan C. Exploiting exosomes in cancer liquid biopsies and drug delivery. Advanced Healthcare Materials 8, e1801268 (2019).
Peng Y, Bariwal J, Kumar V, Tan C*, Mahato RI * (co-corresponding authors). Organic nanocarriers for delivery and targeting of therapeutic agents for cancer treatment. Advanced Therapeutics 3, 1900136 (2020).
Tan C, Waldmann TA. Bench-to-bedside translation of interleukin-15 for immunotherapy: principles and challenges. Expert Opin Drug Deliv 17, 895-8 (2020).
Wang M, Yang X, Pan Z, Wang Y, De La Cruz LK, Wang B, Tan C. Towards “CO in a pill”: pharmacokinetic studies of carbon monoxide prodrugs in mice. J Control Release 327, 174-85 (2020).
Xin X, Kumar V, Lin F, Kumar V, Bhattarai R, Bhatt VR, Tan C*, Mahato RI* (co-corresponding authors). Redox-responsive nano platform for code livery of miR-519c and gencitabine for pancreatic cancer therapy. Science Advances in press (2020).
Postdoctoral Positions Available:
Postdoctoral training opportunities are available in the field of pharmaceutics and immunology. Enthusiastic candidates with a recent PhD in pharmaceutics, immunology or the related disciplines are encouraged to apply. Experience with controlled-release formulations such as nanodelivery systems and hydrogels, animal studies, mucosal immunity, T cell and NK cell biology, immune checkpoint blockade, and flow cytometry is preferred. Candidates should be self-motivated, career oriented, and should be capable of troubleshooting and team working. Excellent verbal and written communication skills, strong passion for research, and first-author publications in peer-reviewed journals are required. For questions or additional information, please contact Dr. Chalet Tan at firstname.lastname@example.org.